Buradasınız

Anasayfa » Content

Sağlıklı Bireylerde ve Kardiyovasküler Hastalığı Olan Olgularda Adiponektin, Leptin, Rezistin Düzeylerinin Değerlendirilmesi: Bursa Çalışması

Serum Levels of Leptin, Adiponectin and Resistin in People with Cardiovasculer Disease and Healthy Adults: Bursa Study

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2011

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
In the Turkish population, prevalence of CVD and deaths related to this are higher than western society. Recently, state of various risk agent factors that is related to CVD in our population has been determined. However, there is no systematic study and data about state of adipokin levels in healty adults and CVD patients. In our study, we have purposed to measure levels of adipokines on healthy adults and angio patients and to analyse the relationship between CVD and these levels. 243 healthy subjects who are between 18-45 years old and 101 angio patients who was operated on coronary angiography have been included in the study. Gensini scores were determined in CVD patients. Serum levels of leptin and resistin, in CVD group were higher (p<0.05, p<0.01, respectively) and adiponectin levels were lower (p<0.01) than the observed values for healthy adults. There was no significant difference between adiponectin, leptin and resistin levels of as the basis of Gensini scores. Serum levels of leptin and adiponectin, in females were higher (p<0.001) than the observed values for males. These changes in adipokine levels may contribute to high prevalence in Turkish population expecially in males.
Bookmark/Search this post with
Abstract (Original Language): 
Türk toplumunda KVH prevalansı ve buna bağlı ölümler batı toplumlarına göre yüksektir. Son yıllarda, toplumumuzdaki KVH ile ilgili çeşitli risk faktörlerinin durumu üzerinde çalışılmaktadır. Ancak, dolaşımdaki adipokinlerin düzeyleri ile ilgili sistematik bir çalışma ve veri yoktur. Çalışmamızda sağlıklı erişkinlerde ve anjiyo hastalarında adipokinlerin düzeylerini ölçmeyi, KVH ile arasındaki ilişkiyi incelemeyi amaçladık. Çalışmamıza 18-45 yaşları arasında sağlıklı 243 sağlıklı gönüllü erişkin koroner anjiyografisi yapılan 101 anjiyo hastası alındı. Anjiyo hastalarının Gensini skorları hesaplandı. KVH olan gruptaki hastaların leptin (p<0.05) ve rezistin (p<0.01) düzeyleri sağlıklı gruptaki katılımcılara göre yüksek, adiponektin düzeyleri ise düşük (p<0.01) bulundu. KVH olan hastalar Gensini skorlamasına göre hafif ve ağır darlık olan gruplara ayrıldığında adiponektin, leptin ve rezistin seviyeleri arasında anlamlı bir fark bulunmadı. Sağlıklı erkek bireylerde adiponektin ve leptin düzeyleri sağlıklı kadın katılımcılara göre düşük (p<0.001) bulundu. Adipokin düzeylerindeki bulunan bu değişiklikler toplumumuzda ve özellikle erkeklerde görülen yüksek KVH prevalansına katkıda bulunabilir.
FULL TEXT (PDF): 
PDF icon arastirmax-saglikli-bireylerde-kardiyovaskuler-hastaligi-olan-olgularda-adiponektin-leptin-rezistin-duzeylerinin-degerlendirilmesi-bursa-calismasi.pdf
  • 2
77-81
  • Turkish

REFERENCES

References: 

1. Onat A. Risk factors and cardiovascular disease in Turkey.
Atherosclerosis 2001;156:1-10.
2. Onat A, Dursunoglu D, Sansoy V. Relatively high coronary
death and event rates in Turkish women. Relation to three
major risk factors in five-year follow-up of cohort. Int J Cardiol
1997;61:69-77.
3. Razum O. Is mortality from ischaemic heart disease in Turkey
among the highest in Europe? Aytherosclerosis 2001;158:499-
500.
4. Mahley RW, Pepin J, Palaoğlu E, Malloy M, Kane J, Bersot T.
Low levels of high density lipoproteins in Turks, a population
with elevated hepatic lipase: hihg density lipoprotein
charecterization and gender-spesific effects of apolipoprotein E
genotype.J.Lipd Res 2000; 41:1290-301.
5. Havel PJ. Control of energy homeostasis and insulin action by
adipocyte hormones: leptin, acylation stimulating protein and
adiponectin. Curr Opin Lipidol 2002;13:51-9.
6. Rajala MW, Scherer PE. Minireview: the adipocyte at the
crossroads of energy homeostasis, inflammation, and
atherosclerosis. Endocrinology 2003;144:3765-73.
7. Kratchmarova DE, Kalume B, Blagoev PE, Scherer AV,
Podtelejnikov H, Molina PE, et al. A proteomic approach for
identification of secreted proteins during the differentiation of
3T3-L1 preadipocytes to adipocytes. Mol Cell Proteomics
2002;1:213-22.
8. Berg AH, Scherer PE. Adipose tissue, inflammation, and
cardiovascular disease. Circ Res 2005;96:939-49.
9. Söylemez N, Demirbağ R, Sezen Y, Yıldız A, Akpınar O.The
levels of the leptin and adiponectin according to body mass
index and their relationship with oxidative parameters.Anadolu
Kardiyol Derg. 2010;10(5):391-6.
10. Demirci H, Yilmaz M, Ergun MA, Yurtcu E, Bukan N, Ayvaz
G. Frequency of adiponectin gene polymorphisms in polycystic
ovary syndrome and the association with serum adiponectin,
androgen levels, insulin resistance and clinical
parameters.Gynecol Endocrinol. 2010;26(5):348-55.
11. Gensini GG. A more meaningful scoring system for
determining the severity of coronary heart disease. Am J
Cardiol 1983;51:606-11.
12. Mahley RW, Palaoğlu E, Atak Z, Dawson-Pepin J, Langlois AM, Cheung V ve ark. Turkish Hearth Study: lipids, lipoproteins,
and apolipoproteins. J of Lipid Res.1995; 36:839-59.
13. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm
EB. Plasma adiponectin levels and risk of myocardial infarction
in men. Journal of the American Medical Association
2004;291:1730-7.
14. Hasan-Ali H, Abd El-Mottaleb NA, Hamed HB, Abd-Elsayed
A.Serum adiponectin and leptin as predictors of the presence
and degree of coronary atherosclerosis. Coron Artery Dis 2011,
March 4 (Epub ahead).
15. Göksoy H, Dursunoğlu D, Oztürk M, Rota S.The association
between serum adiponectin levels and the severity of coronary
artery lesions on the angiogram.. Turk Kardiyol Dern Ars.
2009;37; 241-45
16. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J,
Gaw A, Sattar N. Plasma leptin and the risk of cardiovascular
disease in the West of Scotland Coronary Prevention Study
(WOSCOPS). Circulation 2001;104:3052-6.
17. Sierra-Honigmann MR, Nath AK, Murakami C, GarciaCardena G, Papapetropoulos A, Sessa WC, Madge LA,
Schechner JS, Schwabb MB, Polverini PJ, Flores-Riveros JR.
Biological action of leptin as an angiogenic factor. Science
1998;281:1683-6. Adipokin Düzeyleri; Bursa Çalışması
81
18. Bodary PF, Westrick RJ, Wickenheiser KJ, Shen Y, Eitzman
DT. Effect of leptin on arterial thrombosis following vascular
injury in mice. Journal of the American Medical Association
2002;287:1706-9.
19. Pyrzak B, Ruminska M, Popko K, Demkow U. Adiponectin as
a biomarker of the metabolic syndrome in children and
adolescents. Eur J Med Res. 2010, 15:147-51
20. Yamamato Y, Hirose H, Saito I, Tomita M, Taniyama M,
Matsubara K. et al. Correlation of the adipocyte-derived protein
adiponectin with insulin resistance index and serum highdensity lipoprotein-cholesterol, independent of body mass
index, in the Japanese population, Clinical Science (2002) 103,
137-142
21. McConway MG, Johnson D, Kelly A, Griffin D, Smith J,
Wallace AM. Differences in circulating concentrations of total,
free and bound leptin relate to gender and body composition in
adult humans. Ann Clin Biochem 2000;37:717-23
22. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H,
Nagaretani H. et al. Androgens decrease plasma adiponectin, an
insülin-sensitizing adipocyte-derived protein. Diabetes.
2002;51(9):2734-41.
23. Shi H, Seeley RJ, Cleqq DJ. Sexual differences in the control of
energy homeostasis. Front Neuroendocrinol. 2009;30(3):396-
404.
24. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader
DJ. Resistin is an inflammatory marker of atherosclerosis in
humans. Circulation 2005;111:932-9.
25. Lubos CM, Messow RS, Rupprecht HJ, Espinola-Klein C,
Bickel C, Peetz D, Post F, Lackner KJ, Tiret L, Munzel T,
Blankenberg S. Resistin, acute coronary syndrome and
prognosis results from the AtheroGene study Edith.
Atherosclerosis 2007;193:121-8.
26. Steppan CM & Lazar MA. The current biology of resistin.
Journal of International Medicine 2004;255:439-47.
27. Savage DB, Sewter CP, Klenk, ES, Segal DG, Vidal-Puig A,
Considine RV & O’Rahilly S. Resistin/Fizz3 expression in
relation to obesity and peroxisome proliferator-activated
receptoraction in humans. Diabetes 2001;50: 2199-202.

Thank you for copying data from http://www.arastirmax.com